Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Solara Active Pharma Sciences Ltd Performance

Today's Low
487.15
arrowIcon
Today's High
515.95
52 Wk Low
286.00
arrowIcon
52 Wk High
606.40


Open

506.45

Traded Value (Cr)

15.68 Cr

Prev. Close

505.4

VWAP

497.5

Volume

2,16,825

Face Value

10

Solara Active Pharma Sciences Ltd Fundamentals

Market Cap
₹ 1,785 Cr
P/E Ratio (TTM)
0.00
P/B Ratio
1.22
Debt to Equity
0.67
ROE
-1.86 %
EPS (TTM)
0.00
Dividend Yield
0.60%
Book Value
406.55

Click here to know more about Fundamentals

Solara Active Pharma Sciences Ltd Financials

Solara Active Pharma Sciences Ltd Financials

Solara Active Pharma Sciences Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Others 31.85 % 30.23 % 23.36 % 22.22 %
Promoters 30.49 % 30.49 % 37.19 % 39.31 %
Retail 20.15 % 20.95 % 19.84 % 18.06 %
FII 15.80 % 16.62 % 17.86 % 18.71 %
Mutual Funds 1.71 % 1.71 % 1.75 % 1.71 %

Others

31.85%

Promoters

30.49%

Retail

20.15%

FII

15.80%

Mutual Funds

1.71%

Others

30.23%

Promoters

30.49%

Retail

20.95%

FII

16.62%

Mutual Funds

1.71%

Others

23.36%

Promoters

37.19%

Retail

19.84%

FII

17.86%

Mutual Funds

1.75%

Others

22.22%

Promoters

39.31%

Retail

18.06%

FII

18.71%

Mutual Funds

1.71%

Resistance and Support

₹521.20

PIVOT

resistance-arrow
Resistance
First Resistance₹535.800
Second Resistance₹558.550
Third Resistance₹573.150
support-arrow
Support
First Resistance₹498.450
Second Resistance₹483.850
Third Resistance₹461.100
RSI54.047
MACD36.871
ADX51.955
CCI-7.141

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day216,825158,47450.07
Week293,355122,82542.67
1 Month1,008,295204,61843.65
6 Months216,82599,94546.09

About Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd is a Public Limited Company incorporated in February 23, 2017 under the provisions of Companies Act, 2013 to undertake business in manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of and dealing in active pharmaceutical ingredients (APIs). The Company has six APIs manufacturing plants located in Ambernath, Mangalore, Mysore, Puducherry, Vishakhapatnam, and Cuddalore with a capacity of over 2,000 kilo litres and two R&D Centres in Chennai and Bangalore. The business is spread across 75 countries globally with extensive operations in key markets of North America, Europe, Japan, South Korea, the Middle East and North Africa. The Company offer rich basket of niche high-value products for global markets. The Company has developed 80+ commercial APIs predominantly in anthelmintic, anti-malarias, anti-infective, neuromuscular insomnia and anti-psychotic hyperkalemia segments, among others. It also reinforce entry barriers to competition and build strong intrinsic value through market specific launches. Apart from this, the Solara Active has two research and development units - in Bengaluru and Chennai - equipped with state-of-the-art facilities and a pipeline of 25+ products, at different stages of development. These drugs primarily deal with anthelmintic, anti-malarias, beta blockers, muscle relaxants, novel oral anticoagulants, anti-infective and other niche segments. The Company's manufacturing facilities enjoy regulatory approvals from the United States Food and Drug Administration (USFDA); European Directorate for the Quality of Medicines (EDQM); Korea Food & Drug Administration (KFDA) - South Korea; Euro Zone - Good Manufacturing Practice (EUGMP) - Danish, World Health Organization (WHO) - Geneva; Medicines and Healthcare products Regulatory Agency (MHRA); Federal Commission for the Protection against Sanitary Risk (Cofepris) - Mexico; Therapeutic Goods Administration (TGA) - Australia; Pharmaceuticals and Medical Devices Agency (PMDA) - Japan. During the year, the Company's wholly owned subsidiary Strides Chemicals Private Limited (Strides Chemicals) was amalgamated with the Company. The Honourable National Company Law Tribunal, Mumbai Bench, approved the Scheme of Amalgamation of Strides Chemicals with Company on December 20, 2019. Accordingly, the Company has fixed effective date for the Scheme is February 01, 2020. The appointed date for scheme is September 01, 2018. The Company has completed filing of necessary documents for giving effect to the Scheme. Consequent to amalgamation, the entire equity shares held by Company in Strides Chemicals stands cancelled. The Board of Directors of Company at its meeting held on April 09, 2021 have approved Scheme of Amalgamation for merger of Aurore Life Science Private Limited, Empyrean Lifesciences Private Limited and Hydra Active Pharma Sciences Private Limited (Transferor Companies) into the Company (Transferee Company) in terms of Section 230 to 232 of the Companies Act, 2013. The Scheme is subject to necessary statutory and regulatory approvals including the approvals of National Company Law Tribunal, the shareholders and creditors of each of the companies. The Appointed Date for the said Scheme of Amalgamation is April 01, 2021 or such other date as may be agreed between the Transferor Company and Transferee Company and approved by National Company Law Tribunal. The Company's new Greenfield plant situated at SEZ unit, Plot No.:3B,3C,3D, Part 2 and 2A-1, APIIC APSEZ, Atchutapuram Village, Rambilli Mandal, Visakhapatnam - 531011, Andhra Pradesh, has commenced commercial production in 2021. The Board at its meeting held on February 3, 2021 has approved to acquire 4,87,000 additional share capital in Sequent Penems Private Limited, subsidiary company of Solara. Subsequent to year end, the said transaction is completed and Sequent Penems Private Limited is wholly owned subsidiary of Company with effect from April 27, 2021. The achievements received by the Company in FY 2020-21 were as follows: The Ambernath facility received Certificate of Merit from National Safety Council, Maharashtra for Lowest Average Accident Frequency Rate'. They improved EcoVadis Score from 31 to 47 and was awarded a bronze medal in recognition of Sustainability achievement. The Mangalore site of company was certified for ISO 14001 and ISO 45001. Besides, they conducted a Red Tag Event to identify unsafe conditions and acts to make workplace injury nd incident free. All employees and contractors actively participated in the event. .

Managing Director

Jitesh Devendra

Founded

2017

NSE Symbol

SOLARA

Solara Active Pharma Sciences Ltd Management

NameDesignation
Aditya PuriChairman & Non Executive Dir.
Nirmal P BhogilalIndependent Non Exe. Director
Vineeta RaiIndependent Non Exe. Director
RAJAGOPALAN RAMAKRISHNANIndependent Non Exe. Director
Kausalya SanthanamIndependent Non Exe. Director
ANKUR NAND THADANINon Executive Director
Arun KumarNon Executive Director
S HariharanExecutive Director & CFO
Jitesh DevendraManaging Director & CEO
Poorvank PurohitManaging Director & CEO
Rajendra Kumar SrivastavaAdditional Director
Rajiv Vijay NabaAdditional Director

Solara Active Pharma Sciences Ltd News

Solara Active Pharma Sciences completes divestment of 100% stake in SeQuent Penems
Board of Solara Active Pharma Sciences approves sale of subsidiary - SeQuent Penems
At meeting held on 25 March 2024
Solara Active Pharma appoints Arun Kumar Baskaran as CFO
The pharmaceuticals company said that its board has approved the appointment of Arun Kumar Baskaran as chief financial officer (CFO) of the company with effect from 8 March 2024.
Solara Active Pharma Sciences to table results
On 14 February 2024
Solara Active Pharma Sciences reports consolidated net loss of Rs 17.16 crore in the September 2023 quarter
Sales rise 25.67% to Rs 425.24 crore
Solara Active Pharma Sciences to table results
On 14 November 2023
Solara Active Pharma Sciences to convene AGM
On 15 September 2023
Solara Active Pharma slides as net loss widens to Rs 19 cr in Q1
Solara Active Pharma Sciences tumbled 7.28% to Rs 368.15 after the company reported net loss of 19.11 crore in Q1 FY24 as compared with Rs 16.43 crore posted in Q1 FY23.
Solara Active Pharma Sciences reports consolidated net loss of Rs 19.11 crore in the June 2023 quarter
Sales rise 6.74% to Rs 352.31 crore
Solara Active Pharma Sciences to declare Quarterly Result
On 11 August 2023

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,58,616 Cr
₹ 1,494.65
(-1.78 %)
86.97
CIPLA₹ 1,09,708 Cr
₹ 1,358.80
(-1.87 %)
33.36
DIVISLAB₹ 1,00,611 Cr
₹ 3,789.95
(-3.50 %)
73.75
DRREDDY₹ 98,044 Cr
₹ 5,877.35
(-2.96 %)
22.59
ZYDUSLIFE₹ 97,423 Cr
₹ 968.20
(-3.72 %)
36.23

Solara Active Pharma Sciences Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Solara Active Pharma Sciences Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Solara Active Pharma Sciences Ltd's share price is ₹495.45 as of May 9, 2024

Solara Active Pharma Sciences Ltd's P/E ratio is 0.00 times as of May 9, 2024.

Solara Active Pharma Sciences Ltd's most recent financial reports indicate a price-to-book ratio of 1.22, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Solara Active Pharma Sciences Ltd's market is 1,785 Cr as on May 9, 2024.

The current financial records of Solara Active Pharma Sciences Ltd show a -1.86% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Solara Active Pharma Sciences Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Solara Active Pharma Sciences Ltd's 52-week high and low as of May 9, 2024 are ₹515.95 and ₹487.15 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Solara Active Pharma Sciences Ltd stands at 30.49%. During the same period, Institutional Investors have shown a slight decrease in their holdings, dropping from 16.62% to 15.80%.